# Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study

> **NCT02051387** · PHASE1 · COMPLETED · sponsor: **Central Institute of Mental Health, Mannheim** · enrollment: 74 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Cannabidiol CR
- **DRUG:** Cannabidiol
- **DRUG:** Amisulpride
- **DRUG:** Olanzapine
- **DRUG:** Quetiapine
- **DRUG:** Risperidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02051387
- **Lead sponsor:** Central Institute of Mental Health, Mannheim
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2018-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02051387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02051387, "Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02051387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*